New eye scanner may spot blindness risk years earlier
NCT ID NCT02395757
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether a device called MAIA, which measures light sensitivity in the retina, can predict when intermediate age-related macular degeneration (AMD) progresses to the advanced stage. Researchers followed 182 people who already had advanced AMD in one eye and intermediate AMD in the other. The goal was to see if microperimetry could catch early warning signs before vision loss occurs, allowing for earlier treatment and better outcomes.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could allow doctors to detect AMD progression earlier and start treatment sooner to preserve vision.
- What could go wrong
- This is an observational study, not a treatment trial. The device may not reliably predict progression, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
182 people
The number who actually took part.
- Started
-
Sep 2015
- Finished
-
Jan 2020
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient aged 50 years or over; * Patient who has given their free, informed, signed consent; * Patient with a French social security number or equivalent cover; * Patient presenting one eye with stage 4 AMD (according to the AREDS classification), and drusen in the fellow eye (study eye) with at least one drusen with a diameter of over 125 microns and/or extra- foveal atrophy (stage 3 AREDS); * Patient who is willing and able to attend all the clinical appointments required for the study and complete all the related procedures. Exclusion Criteria: * Patient aged under 50 years; * Patient who refuses to take part in the study; * Woman who is pregnant or breastfeeding; * Protected adult as set out in French law (French Public Health Law); * Patient presenting a study eye with stage 1, 2 or 4 AMD (AREDS classification); * Patient presenting another maculopathy in the study eye; * Area alteration (cornea, lens, vitreous humour) which makes it impossible to carry out and interpret the microperimetry correctly; * Patient due to undergo cataract surgery in the study eye during the 2-year study period; * Patients who cannot be followed up for the full 2 years; * Patients participating simultaneously in other studies which may interfere with the study results (in either eye).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Stage 3 age related macular degeneration (areds classification) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospice Civils de Lyon
Lyon, 69000, France